NeoStem to present at two investor conferences this month, including Proactive Investors One2One Forum

International biopharmaceutical company NeoStem (AMEX:NBS) said Wednesday that it will present at the Proactive Investors One2One Investor Forum on June 16, as well as the OneMedForumNY on June 23.

The Proactive Investors One2One Investor Forum will be held at the Denver Omni Hotels and Resorts, 500 Interlocken Boulevard in Denver, Colorado. The presentations will be from 6:00 pm to 7:30 pm MST on Thursday, June 16.

The stem cell-focused company's vice president of business developement, Jason Kolbert, will update the audience on NeoStem's current position, and will take questions during the reception. To register for the event, please visit http://www.proactiveinvestors.com/register/event_details/50.

Meanwhile, OneMedForumNY 2011 is the sixth OneMedForum conference, and the second in New York, featuring presentations by over 70 emerging medical technology companies. The event will take place on June 23 and 24 at the Roosevelt Hotel in New York City, 45 East 45th Street at Madison Avenue. NeoStem will present at 11:15 AM EDT on June 23 in the Plaza Room. To register for the event, please visit http://www.onemedplace.com/forum/registration.

"NeoStem continues to position itself to be an emerging leader in the paradigm shift to cell-based therapeutics," said Kolbert.

"Our acquisition of Progenitor Cell Therapy provides NeoStem with core expertise to facilitate this transition. Right now we are focused on acquiring assets that are ready for Phase II clinical trials, leveraging PCT's manufacturing and NeoStem's collection model and expertise."

Since starting out as a provider of adult stem cell collection and storage services, New York-based NeoStem has since branched out into cell therapeutics, focused on using stem cells to help cure disease.

In January, the company acquired Progenitor, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US. Progenitor has performed over 30,000 cell therapy procedures and has processed and stored over 18,000 cell therapy products.

But aside from this, the company is benefiting significantly from its Chinese pharmaceuticals business, reporting pharmaceutical revenues of $18.1 million in the first quarter, a 15% growth over the year-ago period. NeoStem owns a 51% stake in Chinese generic pharmaceutical company Suzhou Erye.

"We look forward to executing on important milestones in the near future and to sharing our vision, progress and current outlook with the investor community," said chairman and CEO, Dr. Robin L. Smith.